A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA)

Current Medical Research and Opinion

Volumn 23, Issue 10, 2007, Pages 2313-2323

  Wolf, Jürgen ^a   Janssen, Firmin ^b   Lublin, Henrik ^c   Salokangas, Raimo K R ^d   Allain, Hervé ^e   Smeraldi, Enrico ^f   Bernardo, Miguel ^g   Millar, Helen ^h   Pans, Miranda ⁱ   Adelbrecht, Christine ⁱ   Laughton, Jim ^j   Werner, Christian ^k   Maier, Wolfgang ^l  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Psychiatrische Kliniek Sint Annendael   (Belgium)

^c Unit for Psychotherapy Education and Research   (Denmark)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITÉ DE RENNES 1   (France)

^f UNIVERSITY OF MILAN   (Italy)

^g HOSPITAL CLÍNIC   (Spain)

^h NHS TAYSIDE   (United Kingdom)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j Daiichi Pharmaceuticals UK Ltd   (United Kingdom)

^k Otsuka Pharma GmbH   (Germany)

^l UNIVERSITY OF BONN   (Germany)

more..

Author keywords

Aripiprazole; Atypical antipsychotics; Effectiveness; Naturalistic study; Outpatient; Schizophrenia

Indexed keywords

AMISULPRIDE; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIMIGRAINE AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; BENPERIDOL; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; HYPNOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE; PERAZINE; PERPHENAZINE; PIPOTIAZINE; QUETIAPINE; RISPERIDONE; SEDATIVE AGENT; SULPIRIDE; ZIPRASIDONE;

ADULT; AGED; AKATHISIA; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TREATMENT OUTCOME; VOMITING;

ANTIPSYCHOTIC AGENTS; EUROPE; HUMANS; PIPERAZINES; PROSPECTIVE STUDIES; QUESTIONNAIRES; QUINOLONES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 35648970593     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X225448     Document Type: Article

References (25)

1. Jaffe AB, Levine J. Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia. J Clin Psychiatry 2003;64(Suppl 17):3-6
2. Seeman MV. Clinical trials in psychiatry: do results apply to practice? Can J Psychiatry 2001;46:352-5
3. Stahl SM. Does evidence from clinical trials in psychopharmacology apply in clinical practice? J Clin Psychiatry 2001;62:6-7
4. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003;29:15-31
5. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005;353:1209-23
6. Haro JM, Edgell ET, Novick D, et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005;111:220-31
7. Fleischhacker WW, Keet IP, Kahn RS. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr Res 2005;78:147-56
8. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004;18:251-67
9. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-71
10. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90
11. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-36
12. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325-37
13. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(Suppl. 18):47-56
14. Guy W. Clinical Global Impressions (CGI). ECDEU assessment manual for psychopharmacology US Department of Health, Education, and Welfare publication (ADM) 76-338. Rockville (MD): National Institute of Mental Health; 1976. p. 218-22
15. Tandon R, Devellis RF, Han J, et al. Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder. Psychiatry Res 2005;136:211-21
16. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-56
17. Tandon R, Marcus R, Stock E, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 2006;84:77-89
18. Christensen AF, Poulsen J, Nielsen CT, et al. Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study. Acta Psychiatr Scand 2006;113:148-53
19. Day JC, Bentall RP, Roberts C, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry 2005;62:717-24
20. Karow A, Schnedler D, Naber D. What would the patient choose? Subjective comparison of atypical and typical neuroleptics. Pharmacopsychiatry 2006;39:47-51
21. Wetzel H, Hillert A, Grunder G, Benkert O. Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms. Am J Psychiatry 1994;151:1499-502
22. Correll CU. Real-life switching strategies with second-generation antipsychotics. J Clin Psychiatry 2006;67:160-1
23. Weiden PJ, Miller AL, Lambert TJ, Buckley PF. The art and science of switching antipsychotic medications, part 2. J Clin Psychiatry 2007;68:e02
24. Abilify. Abilify package insert. Princeton (NJ): Bristol-Myers Squibb, Co.; 2006
25. Cutler AJ, Marcus RN, Hardy SA, et al. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectrums 2006;11:691-702